Payments, promotion, and the purple pill

Accepted

Journal Article

Understanding competition in the US drug market requires knowing how sensitive demand is to prices. The relevant prices for insured consumers are copayments. There are many studies of copayment elasticity in the health literature, but they are of limited applicability for studies of competition. Because of a paucity of data, such studies typically control for neither competitor copayment nor advertising. Whereas previous studies examined copayment sensitivity when copayments for branded drugs move in unison, this study examines copayment sensitivity when copayments diverge. This study uses unique panel data of insurance copayments and utilization for 77 insurance groups, as well as data on advertising. The results indicate that demand can be much more sensitive to copayment than previously recognized. Manufacturers selling drugs with higher copayments than branded competitors can lose substantial market share. Manufacturers can offset the loss of demand by increasing advertising to physicians, but it is costly. © 2013 John Wiley & Sons, Ltd.

Full Text

Duke Authors

Cited Authors

  • Ridley, DB

Published Date

  • 2013

Published In

PubMed ID

  • 25491652

Pubmed Central ID

  • 25491652

Electronic International Standard Serial Number (EISSN)

  • 1099-1050

International Standard Serial Number (ISSN)

  • 1057-9230

Digital Object Identifier (DOI)

  • 10.1002/hec.3005

Language

  • eng

Citation Source

  • Scopus